Prime Medicine, Inc. is a Pharmaceuticals company in the United States that specializes in genetic therapies using their innovative Prime Editing technology. With an ESG score of 27.7, they are considered a medium risk company. Prime Editing technology helps treat various diseases by restoring normal genetic function.